{"id":"W2041406002","doi":"10.2147/tcrm.s30159","title":"Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation","year":2014,"lang":"en","type":"review","venue":"Therapeutics and Clinical Risk Management","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Janssen Research and Development; Bayer HealthCare","keywords":"Rivaroxaban; Medicine; Apixaban; Atrial fibrillation; Edoxaban; Stroke (engine); Dabigatran; Warfarin; Vitamin K antagonist; Internal medicine; Population; Anticoagulant; Cardiology; Clinical trial; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002228846,0.0003867232,0.001939905,0.0002784862,0.00009344983,0.00008508692,0.0001339073,0.000351593,0.00002920163],"category_scores_gemma":[0.0001042215,0.0003012775,0.001195622,0.0001740125,0.0000638136,0.00007510786,0.0001208633,0.0002648217,0.00003187712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005914103,"about_ca_system_score_gemma":0.00004741003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001764541,"about_ca_topic_score_gemma":0.00002266815,"domain_scores_codex":[0.9967537,0.0004664291,0.0015318,0.0006386421,0.0003027304,0.0003067282],"domain_scores_gemma":[0.9980527,0.0005597752,0.0007086141,0.0004888399,0.00005627694,0.0001338593],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00032008,0.00002528705,0.007023785,0.002868511,0.001201737,0.000003286823,0.00001037716,0.000006345649,1.113157e-8,0.003833122,0.00002107909,0.9846864],"study_design_scores_gemma":[0.003844263,0.001324283,0.003910069,0.00146595,0.01014788,0.000002108312,0.0000269317,0.001630958,3.693464e-8,0.003458957,0.9738677,0.0003208194],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002958278,0.9826318,0.003952469,0.0002996277,0.00106869,0.007913013,0.00003971152,0.0001122801,0.001024105],"genre_scores_gemma":[0.0006383961,0.9922029,0.002391866,0.0001234965,0.001964635,0.000009894045,0.000337615,0.00006193769,0.002269262],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9843656,"threshold_uncertainty_score":0.9999439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2331200978377106,"score_gpt":0.508692976891979,"score_spread":0.2755728790542684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}